Tag: Calvin Chen

TWi Biotechnology initiates AC-203 phase 2 trial for Epidermolysis Bullosa

pharmanewsdaily- October 21, 2018

TWi Biotechnology, a Taiwanese biotech company, has announced the enrollment of the first patient in a phase 2 trial evaluating AC-203 for the treatment of ... Read More